CHAMPION IRON TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON AUGUST 27, 2025 (MONTRÉAL) / AUGUST 28, 2025 (SYDNEY)
The specific details for the Meeting are as follows:
A live audio webcast will be available the day of the meeting and the webcast recording will be accessible through Champion's website at www.championiron.com/investors/events-presentations.
Access to the webcast:
About Champion Iron Limited
Champion, through its wholly-owned subsidiary Quebec Iron Ore Inc., owns and operates the Bloom Lake Mining Complex located on the south end of the Labrador Trough, approximately 13 kilometres north of Fermont, Québec. Bloom Lake is an open-pit operation with two concentration plants that primarily source energy from renewable hydroelectric power, having a combined nameplate capacity of 15M wmt per year that produce lower contaminant high-grade 66.2% Fe iron ore concentrate with a proven ability to produce a 67.5% Fe direct reduction quality iron ore concentrate. Benefiting from one of the highest purity resources globally, Champion is investing to upgrade half of Bloom Lake's mine capacity to a direct reduction quality pellet feed iron ore with up to 69% Fe. Bloom Lake's high-grade and lower contaminant iron ore products have attracted a premium to the Platts IODEX 62% Fe iron ore benchmark. Champion ships iron ore concentrate from Bloom Lake by rail, to a ship loading port in Sept-Îles, Québec, and has delivered its iron ore concentrate globally, including in China, Japan, the Middle East, Europe, South Korea, India and Canada. In addition to Bloom Lake, Champion owns the Kamistiatusset mining properties, a project with an expected annual production of 9M wmt per year of direct reduction quality iron grading above 67.5% Fe, located near available infrastructure and only 21 kilometres southeast of Bloom Lake. On July 21, 2025, Champion entered into a definitive framework agreement with Nippon Steel Corporation and Sojitz Corporation to form a partnership for the shared ownership and potential development of the Kami project. Champion also owns a portfolio of exploration and development projects in the Labrador Trough, including the Cluster II portfolio of properties, located within 60 kilometres south of Bloom Lake.
For additional information on Champion Iron Limited, please visit our website at: www.championiron.com.
This press release has been authorized for release to the market by the CEO of Champion Iron Limited, David Cataford.
SOURCE Champion Iron Limited
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
24 minutes ago
- Cision Canada
BRP Donates $500,000 of Lynx Apparel to the Healthy Horizons Foundation in Support of Northern Communities Français
VALCOURT, QC, Aug. 15, 2025 /CNW/ - BRP Inc. (TSX: DOO) (NASDAQ: DOOO) announced today that it has donated over CAD $500,000 worth of Lynx apparel to 7 Northern Communities in partnership with the Healthy Horizons Foundation (HHF). Through its Ride Out Intimidation progra m, BRP has been partnering since 2023 with the HHF, which is dedicated to improving the health and well-being of youth in the northern communities. "The Healthy Horizons Foundation is a key partner of BRP's Ride Out Intimidation program. From providing essential winter apparel to investing in the Northy Club after school program, the work that we do with HFF is about empowering youth, fostering safe environments, and building a brighter future for northern communities," said Elise Auvachez Millot, Vice-President, Public Affairs, Government Relations and Corporate Sustainability at BRP. HHF coordinated logistics, operations, store managers and community leaders to distribute the clothing in seven different northern locations across Canada: St. Theresa Point (MB), Sandy Lake (ON), Pikangikum (ON), Shamattawa (MB), South Indian Lake (MB), Aklavik (NWT), and Tulita (NWT). The donated items were distributed in schools and prioritized to kids first. In total, more than one thousand people benefited from the donation, and as these are small communities, every member was able to receive items. "BRP's support has helped us make a real difference in northern communities. Their generous contributions over the years have helped us expand our reach to even more communities, offering not only quality gear that youth and families wear with pride but also unique spaces where young people feel seen, supported, and empowered," said Jim Caldwell, President of Canadian Retail at The North West Company and Board Member of the Healthy Horizons Foundation. The Northy Club, Powered by BRP In addition to the Lynx apparel donation, BRP and the Healthy Horizons Foundation partnered to launch the Northy Club program in October 2024. The afterschool program is designed to empower students from grades 5 to 8 in Northern Indigenous communities by fostering a safe, structured environment focused on education, personal growth, and healthy lifestyles while integrating BRP's emphasis on anti-bullying and intimidation prevention. The program will return for a second year in the fall of 2025 at St. Theresa Point Middle Years School, and is set to expand based on community need to ensure sustainability and lasting impacts. About the Healthy Horizons Foundation The Healthy Horizons Foundation (HHF) is the charitable foundation of The North West Company, committed to advancing the health and well-being of youth in northern and remote communities. Established in 2015, HHF invests in high-impact programs that align with its core pillars: health & well-being, nutrition & food security, and culture & education. By fostering strategic partnerships and community-led initiatives, HHF creates sustainable opportunities for youth to thrive—empowering the next generation through access, equity, and long-term support. Learn more: About BRP BRP Inc. is a global leader in the world of powersports products, propulsion systems and boats built on over 80 years of ingenuity and intensive consumer focus. Through its portfolio of industry-leading and distinctive brands featuring Ski-Doo and Lynx snowmobiles, Sea-Doo watercraft and pontoons, Can-Am on and off-road vehicles, Quintrex boats, Manitou pontoons and Rotax marine propulsion systems as well as Rotax engines for karts and recreational aircraft, BRP unlocks exhilarating adventures and provides access to experiences across different playgrounds. The Company completes its lines of products with a dedicated parts, accessories and apparel portfolio to fully optimize the riding experience. Committed to growing responsibly, BRP is developing electric models for its existing product lines. Headquartered in Quebec, Canada, BRP had annual sales of CA$7.8 billion from over 130 countries and employed approximately 16,500 driven, resourceful people as of January 31, 2025. Ski-Doo, Lynx, Sea-Doo, Can-Am, Rotax, Manitou, Quintrex, and the BRP logo are trademarks of Bombardier Recreational Products Inc. or its affiliates. All other trademarks are the property of their respective owners.
Cision Canada
24 minutes ago
- Cision Canada
VABYSMO® (faricimab injection) Now Publicly Funded For Macular Edema Secondary to Retinal Vein Occlusion (RVO) and Pre-Filled Syringe (PFS) in Quebec Français
Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs MISSISSAUGA, ON, Aug. 15, 2025 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that VABYSMO ® (faricimab injection) is now publicly funded for macular edema secondary to retinal vein occlusion (RVO) on the Régie de l'assurance maladie du Québec (RAMQ) list of medications. 1 This latest update also includes funding for Vabysmo in a 6.0 mg single-use pre-filled syringe (PFS), providing an additional option and expanded access for patients in Quebec. Vabysmo received Health Canada authorization for treatment of macular edema secondary to retinal vein occlusion (RVO) in July 2024, and the approval of the PFS format in December 2024. 2 "This expansion in coverage for people with RVO in Quebec is welcome news in our mission to advance eye care and provide innovative solutions for people living with serious retinal conditions," said Carlene Todd, Vice President, Access at Roche Pharmaceuticals Canada. "We are deeply committed to ensuring equitable and timely access to our treatments, ensuring that provinces across the country prioritize access to innovative medicines that will ultimately improve the lives of people impacted by vision loss." With this latest listing, Vabysmo is now covered in Quebec for all three of its indications and in both formats, including neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and the latest, macular edema secondary to retinal vein occlusion (RVO). These leading causes of vision loss affect around 70 million people worldwide and can have a serious impact on patients, their families, and caregivers. 3,4,5,6 "The recent reimbursement for RVO in Quebec is a significant step forward for people living with the condition," said Dr. Ananda (Andy) Kalevar, Associate Professor, Department of Ophthalmology at Sherbrooke University, Quebec. "It gives ophthalmologists a valuable treatment option and provides patients with access to a medication that may ultimately offer the best outcomes for their vision." Roche Canada is committed to continuing to work with remaining provincial jurisdictions to make Vabysmo available through public and private drug plans for those living with RVO. About retinal vein occlusion (RVO) RVO is the second most common cause of vision loss due to retinal vascular conditions. It affects an estimated 28 million adults globally, mainly those aged 60 or older, and can lead to severe and sudden vision loss. 3,7 There are two main types of RVO: branch RVO (BRVO), which affects more than 23 million people globally and occurs when one of the four smaller 'branches' of the main central retinal vein becomes blocked; and central RVO (CRVO), which is less common, affecting more than four million people worldwide, and occurs when the eye's central retinal vein becomes blocked. 3,8 The levels of Vascular Endothelial Growth Factor A (VEGF-A) and angiopoietin-2 (Ang-2) are elevated in RVO and it is thought that their increased expression drives disease progression. 9,10 RVO typically results in sudden, painless vision loss in the affected eye because the vein blockage restricts normal blood flow in the affected retina, resulting in ischemia, bleeding, fluid leakage and retinal swelling called macular edema. 7,11,8 The safety and efficacy of Vabysmo for the treatment of macular edema secondary to retinal vein occlusion (RVO) were assessed in two randomised, multi-centre, double-masked, studies in patients with macular edema secondary to BRVO (BALATON) or CRVO/hemiretinal vein occlusion (HRVO) (COMINO). Between Week 24 and Week 72, for patients who received faricimab Q4W/faricimab PTI, 49% of patients in BALATON and 34% of patients in COMINO completed at least one cycle of every 12 weeks (Q12W) and maintained ≥ Q12W dosing without an interval reduction below Q12W through Week 68; 32% of patients in BALATON and 24% of patients in COMINO completed 2 cycles of Q16W through Week 72. 2 About Vabysmo ® (faricimab injection) Vabysmo is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A (VEGF-A). By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to increase vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with wet AMD, DME, and RVO. 2 In Canada, Vabysmo is authorized for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). 2 To date, Vabysmo is approved in more than 100 countries for DME and nAMD, and in over 30 countries for macular edema following retinal vein occlusion (RVO). 12,13,14,15,16,17 About Roche Canada At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies. With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love. And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries. Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast. For more information, please visit or follow Roche Canada on LinkedIn. References [1] RAMQ List of medications. Available at: Accessed on August 14, 2025. [2] Vabysmo Product Monograph, July 25, 2025 [3] Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9:010427. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9:010427. [4] Yau JWY, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556–64. [5] Connolly E, et al. Prevalence of age-related macular degeneration associated genetic risk factors and 4-year progression data in the Irish population. Br J Ophthalmol. 2018;102:1691–95. [6] Bright Focus Foundation. Age-Related Macular Degeneration: Facts & Figures [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [7] Moorfields Eye Hospital, United Kingdom National Health Service Foundation Trust. RVO [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [8] Campochiaro P. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015; 49:67-81. [9] Joussen et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021; 35:1305-1316. [10] Regula JT, et al. Targeting key angiogenic pathways with a bispecific CrossMab optimised for neovascular eye diseases. EMBO Molecular Medicine. 2016; 8:1265–88. [11] Schmidt-Erfurth U, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica. 2019; 242:123-162. [12] U.S. Food and Drug Administration (FDA). Highlights of prescribing information, aflibercept 2 mg. 2022. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [13] FDA. Highlights of prescribing information, Vabysmo. 2022. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [14] FDA approves Genentech's Vabysmo for the treatment of RVO [Internet; cited August 2025]. Available from: Accessed on August 6, 2025 [15] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [16] European Medicines Agency. Summary of product characteristics, Vabysmo, 2022 [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [17] Roche Data on File SOURCE Hoffmann-La Roche Limited (Roche Canada)
Toronto Star
39 minutes ago
- Toronto Star
Aecon Announces Renewal of Normal Course Issuer Bid
TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Aecon Group Inc. (TSX: ARE) ('Aecon') announced today receipt of regulatory approval from the Toronto Stock Exchange (the 'TSX') of its notice of intention to renew its normal course issuer bid (the 'NCIB'). Under the NCIB, Aecon may purchase for cancellation, during the period commencing on August 19, 2025 and ending on the earlier of August 18, 2026 and the date on which Aecon reaches the maximum purchases permitted under the NCIB, up to 3,180,767 common shares of Aecon ('Common Shares'), representing 5% of the issued and outstanding Common Shares. Aecon had a total of 63,615,334 issued and outstanding Common Shares as of August 7, 2025.
